日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy

对不适合接受强化化疗的急性髓系白血病患者进行低剂量阿糖胞苷和维奈托克治疗的风险分层

Wei, Andrew H; Panayiotidis, Panayiotis; Montesinos, Pau; Laribi, Kamel; Ivanov, Vladimir; Kim, Inho; Novak, Jan; Champion, Rebecca; Fiedler, Walter; Pagoni, Maria; Bergeron, Julie; Ting, Stephen B; Hou, Jing-Zhou; Yamauchi, Takahiro; Wang, Jianxiang; Strickland, Stephen A; Savona, Michael R; Lin, Tara L; Enjeti, Anoop; Tiong, Ing Soo; Lee, Sangmin; Roboz, Gail J; Popovic, Relja; Jiang, Qi; Liu, Zihuan; Sun, Yan; Mendes, Wellington; Chyla, Brenda; DiNardo, Courtney D

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

MURANO 研究:VenR 治疗复发/难治性 CLL 患者的最终分析和再治疗/交叉亚组研究结果

Kater, Arnon P; Harrup, Rosemary; Kipps, Thomas J; Eichhorst, Barbara; Owen, Carolyn J; Assouline, Sarit; Lamanna, Nicole; Robak, Tadeusz; de la Serna, Javier; Jaeger, Ulrich; Cartron, Guillaume; Montillo, Marco; Mellink, Clemens; Langerak, Anton W; Chyla, Brenda; Popovic, Relja; Jiang, Yanwen; Millen, Rosemary; Lefebure, Marcus; Thadani-Mulero, Maria; Boyer, Michelle; Seymour, John F

Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia

慢性淋巴细胞白血病患者停药后疾病进展,可使用维奈托克和利妥昔单抗进行再治疗

Brander, Danielle M; Roberts, Andrew W; Kipps, Thomas J; Ma, Shuo; Anderson, Mary Ann; Boyer, Michelle; Blombery, Piers; Popovic, Relja; Roser, Jordan; Liu, Zhuangzhuang; Chyla, Brenda; Seymour, John F

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

一项针对del(17p)慢性淋巴细胞白血病的维奈托克II期临床试验的六年随访和亚组分析

Stilgenbauer, Stephan; Tausch, Eugen; Roberts, Andrew W; Davids, Matthew S; Eichhorst, Barbara; Hallek, Michael; Hillmen, Peter; Schneider, Christof; Schetelig, Johannes; Böttcher, Sebastian; Kater, Arnon P; Jiang, Yanwen; Boyer, Michelle; Popovic, Relja; Ghanim, Majd T; Moran, Michael; Sinai, Wendy J; Wang, Xifeng; Mukherjee, Nabanita; Chyla, Brenda; Wierda, William G; Seymour, John F

Lipid composition differentiates ferroptosis sensitivity between in vitro and in vivo systems

脂质组成决定了体外和体内系统对铁死亡的敏感性。

Park, Vivian S; Pope, Lauren E; Ingram, Justin; Alchemy, Grace A; Purkal, Julie; Andino-Frydman, Eli Y; Jin, Sha; Singh, Sanjana; Chen, Anlu; Narayanan, Priya; Kongpachith, Sarah; Phillips, Darren C; Dixon, Scott J; Popovic, Relja

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

更正:RAS/MAPK通路激活赋予急性髓系白血病细胞MCL-1介导的对BCL-2抑制剂维奈托克的获得性耐药性。

Zhang, Qi; Riley-Gillis, Bridget; Han, Lina; Jia, Yannan; Lodi, Alessia; Zhang, Haijiao; Ganesan, Saravanan; Pan, Rongqing; Konoplev, Sergej N; Sweeney, Shannon R; Ryan, Jeremy A; Jitkova, Yulia; Dunner, Kenneth Jr; Grosskurth, Shaun E; Vijay, Priyanka; Ghosh, Sujana; Lu, Charles; Ma, Wencai; Kurtz, Stephen; Ruvolo, Vivian R; Ma, Helen; Weng, Connie C; Ramage, Cassandra L; Baran, Natalia; Shi, Ce; Cai, Tianyu; Davis, Richard Eric; Battula, Venkata L; Mi, Yingchang; Wang, Jing; DiNardo, Courtney D; Andreeff, Michael; Tyner, Jeffery W; Schimmer, Aaron; Letai, Anthony; Padua, Rose Ann; Bueso-Ramos, Carlos E; Tiziani, Stefano; Leverson, Joel; Popovic, Relja; Konopleva, Marina

Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy

维奈托克单药治疗慢性淋巴细胞白血病患者凋亡机制中复发性基因组改变的鉴定

Popovic, Relja; Dunbar, Fengjiao; Lu, Charles; Robinson, Kenneth; Quarless, Danjuma; Warder, Scott E; Mukherjee, Nabanita; Pesko, John; Souers, Andrew J; Waring, Jeffrey F; Davids, Matthew S; Tausch, Eugen; Stilgenbauer, Stephan; Ross, Jeremy A; Leverson, Joel D; Kim, Su Young; Chyla, Brenda J

A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia

一项针对复发/难治性急性髓系白血病患者的泛溴结构域和末端外抑制剂mivebresib (ABBV-075) 单药或联合venetoclax的I期研究

Borthakur, Gautam; Odenike, Olatoyosi; Aldoss, Ibrahim; Rizzieri, David A; Prebet, Thomas; Chen, Chris; Popovic, Relja; Modi, Dimple A; Joshi, Rujuta H; Wolff, Johannes E; Jonas, Brian A

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

在维奈托克单药治疗后进展的复发/难治性慢性淋巴细胞白血病中加用利妥昔单抗

Handunnetti, Sasanka; Anderson, Mary Ann; Roberts, Andrew W; Davids, Matthew S; Ma, Shuo; Boyer, Michelle; Arzt, Jennifer; Masud, Abdullah Al; Popovic, Relja; Jacobson, Amanda; Kim, Su Y; Seymour, John F

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

维奈托克联合低剂量阿糖胞苷治疗既往未接受治疗的急性髓系白血病患者:一项 Ib/II 期研究的结果

Wei, Andrew H; Strickland, Stephen A Jr; Hou, Jing-Zhou; Fiedler, Walter; Lin, Tara L; Walter, Roland B; Enjeti, Anoop; Tiong, Ing Soo; Savona, Michael; Lee, Sangmin; Chyla, Brenda; Popovic, Relja; Salem, Ahmed Hamed; Agarwal, Suresh; Xu, Tu; Fakouhi, Kaffa M; Humerickhouse, Rod; Hong, Wan-Jen; Hayslip, John; Roboz, Gail J